Medigus anticipates that this code will be used to cover its MUSE platform.
“This Category 1 CPT code represents an important step in establishing coverage for this kind of procedure. We are pleased with the AMA’s recommendation and would like to thank the AGA, ACG, ASGE and SAGES for their leadership, which indicates the medical community’s recognition of the need for alternative and minimally invasive procedures for chronic GERD patients,” said Chris Rowland, CEO of Medigus. “The Category I code should enhance access to these procedures which were created to help enhance both patient care and outcomes.”
More articles on gastroenterology:
Exact Sciences, Ironwood Pharmaceuticals partner for promotion of Cologuard
Gastroenterology technology company to know: Exalenz Bioscience
Vegetarian diet associated with reduced CRC risk
